FluimediX was founded in 2003 to develop the NanoCycler™ platform, based on inventions made by Tomas Ussing, along with SEED Capital Denmark as founding investor in the company.
TAASTRUP, Denmark--(BUSINESS WIRE)--FluimediX, a point-of-care diagnostic company, announced today that PhD HC Ove Öhman has joined the Company’s Board of Directors as a non-executive Director. Mr. Öhman played an instrumental role in the founding and development of Åmic AB, a Swedish diagnostic company. He led Åmic as Chairman, Chief Executive Officer and Vice President R&D for more than 10 years prior to the company being acquired by Johnson & Johnson in 2008. His career spans more than 25 years working in Management and R&D positions with Biacore, Pharmacia and Toolex Alpha as well as Johnson & Johnson. Mr. Öhman is currently a co-founder and Chief Executive Officer of Fiomi Diagnostics AB, a point-of-care diagnostic company.
“We welcome Ove Öhman to the FluimediX Board and look forward to benefitting from his experience as the Company continues to develop high-value diagnostic applications for its NanoCycler™ platform”
“We welcome Ove Öhman to the FluimediX Board and look forward to benefitting from his experience as the Company continues to develop high-value diagnostic applications for its NanoCycler™ platform,” said Ole Bitsch-Jensen, Investment Manager with SEED Capital Denmark and Chairman of the FluimediX Board.
FluimediX also announced that a patent covering the Company’s “contact free cell lysis” technology had recently been issued in China. This patented technology has a number of advantages over existing approaches for inducing cell lysis, including simple implementation, the use of inexpensive components, and the exclusion of harsh chemicals that may otherwise interfere with subsequent processes. The contact free cell lysis technology patent is currently in the PCT phase in the US, Europe and Japan.
Tomas Ussing, CEO and founder of FluimediX, commented, “FluimediX has developed a number of highly innovative and proprietary technologies underlying our NanoCycler™ platform; our contact free cell lysis technology is central to our capability of processing ‘raw’ sample material prior to analysis. We believe that this particular innovation has broad potential for a number of applications beyond our present focus. This new patent further strengthens our broad IP position surrounding our core platform for which we have already received a high degree of potential licensing interest from the diagnostic industry.”
About the NanoCycler™ Platform
The NanoCycler™ is a point-of-care diagnostic platform that identifies the presence of genetic mutations, also called Single Nucleotide Polymorphisms (SNPs), which are relevant to specific medical conditions in order to aid proper diagnosis and treatment. This tabletop device is designed to accept a disposable polymer cartridge on which a number of biochemical reactions are performed on a human saliva sample. The platform utilizes a medium-powered infrared laser diode, which is directed at microfluidic channels and reservoirs. This action instigates microfluidic flow control, thermocycling, cell lysis, mixing, and fluorescence excitation, all of which are basic functions involved in performing complex biochemical analysis. The built-in broad versatility of the NanoCycler™ device will allow multiple tests to be transferred to or developed for the NanoCycler™ platform in the future.
About FluimediX
FluimediX was founded in 2003 to develop the NanoCycler™ platform, based on inventions made by Tomas Ussing, along with SEED Capital Denmark as founding investor in the company. The company is located at The Danish Institute of Technology, where it has access to leading micro technology expertise and facilities. The company has filed several patents on key elements of the technologies behind the NanoCycler™ platform. (www.fluimedix.com)
